In the quest to outshine the broader market, stock pickers diligently seek out stocks with the potential for superior performance. Making the right choices can significantly elevate your wealth.
The closing price of Roivant Sciences Ltd (NASDAQ: ROIV) was $18.41 for the day, down -2.13% from the previous closing price of $18.81. In other words, the price has decreased by -$2.13 from its previous closing price. On the day, 8.28 million shares were traded. ROIV stock price reached its highest trading level at $18.955 during the session, while it also had its lowest trading level at $18.32.
Ratios:
Our analysis of ROIV’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 40.54 and its Current Ratio is at 40.54. In the meantime, Its Debt-to-Equity ratio is 0.02 whereas as Long-Term Debt/Eq ratio is at 0.02.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of. The stock’s future direction. In the most recent recommendation for this company, Citigroup on September 02, 2025, initiated with a Buy rating and assigned the stock a target price of $16.
On February 15, 2024, Wolfe Research started tracking the stock assigning a Outperform rating and target price of $17.Wolfe Research initiated its Outperform rating on February 15, 2024, with a $17 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Oct 15 ’25 when Venker Eric sold 414,683 shares for $16.93 per share. The transaction valued at 7,020,583 led to the insider holds 1,504,959 shares of the business.
Venker Eric sold 318,282 shares of ROIV for $5,426,708 on Oct 16 ’25. The President & Immunovant CEO now owns 1,504,959 shares after completing the transaction at $17.05 per share. On Oct 17 ’25, another insider, Venker Eric, who serves as the President & Immunovant CEO of the company, sold 118,418 shares for $17.06 each. As a result, the insider received 2,020,211 and left with 1,504,959 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ROIV now has a Market Capitalization of 12571852800 and an Enterprise Value of 8638667776. For the stock, the TTM Price-to-Sale (P/S) ratio is 541.19 while its Price-to-Book (P/B) ratio in mrq is 2.89. Its current Enterprise Value per Revenue stands at 371.827 whereas that against EBITDA is -7.523.
Stock Price History:
The Beta on a monthly basis for ROIV is 1.23, which has changed by 0.5967742 over the last 52 weeks, in comparison to a change of 0.18258524 over the same period for the S&P500. Over the past 52 weeks, ROIV has reached a high of $18.85, while it has fallen to a 52-week low of $8.73. The 50-Day Moving Average of the stock is 23.80%, while the 200-Day Moving Average is calculated to be 54.43%.
Shares Statistics:
ROIV traded an average of 7.22M shares per day over the past three months and 8849470 shares per day over the past ten days. A total of 682.23M shares are outstanding, with a floating share count of 415.35M. Insiders hold about 39.18% of the company’s shares, while institutions hold 64.16% stake in the company. Shares short for ROIV as of 1760486400 were 25271869 with a Short Ratio of 3.50, compared to 1757894400 on 36208272. Therefore, it implies a Short% of Shares Outstanding of 25271869 and a Short% of Float of 4.96.
Earnings Estimates
The stock of Roivant Sciences Ltd (ROIV) is currently in the spotlight, with 4.0 analysts actively rating and assessing its market standing.The consensus estimate for the next quarter is -$0.31, with high estimates of -$0.25 and low estimates of -$0.42.
Analysts are recommending an EPS of between -$0.95 and -$1.56 for the fiscal current year, implying an average EPS of -$1.16. EPS for the following year is -$1.3, with 4.0 analysts recommending between -$1.02 and -$1.82.
Revenue Estimates
It is expected that $90B in revenue will be generated in. The current quarter, according to 7 analysts. It ranges from a high estimate of $15M to a low estimate of $1.78M. As of. The current estimate, Roivant Sciences Ltd’s year-ago sales were $29.26MFor the next quarter, 7 analysts are estimating revenue of $7.1M. There is a high estimate of $15M for the next quarter, whereas the lowest estimate is $1.78M.
A total of 9 analysts have provided revenue estimates for ROIV’s current fiscal year. The highest revenue estimate was $47.2M, while the lowest revenue estimate was $2.17M, resulting in an average revenue estimate of $21.43M. In the same quarter a year ago, actual revenue was $29.05MBased on 9 analysts’ estimates, the company’s revenue will be $169.51M in the next fiscal year. The high estimate is $567.77M and the low estimate is $7.87M.
